Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 4, 2002, Pages 304-309

  Molino, Annamaria ^a,d   Pedersini, Rebecca ^a   Micciolo, Rocco ^b   Frisinghelli, Michela ^a   Giovannini, Monica ^a   Pavarana, Michele ^a   Nortilli, Rolando ^a   Santo, Antonio ^a   Manno, Pietro ^a   Padovani, Martina ^a   Piubello, Quirino ^c   Cetto, Gian Luigi ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c Azienda Ospedaliera   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

Author keywords

Breast cancer; Ki 67; Prognosis; Thymidine labeling index

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; THYMIDINE; TRITIUM;

ANALYSIS OF VARIANCE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; ISOTOPE LABELING; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STANDARD;

AUTORADIOGRAPHY; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PROGNOSIS; THYMIDINE; TRITIUM;

EID: 0036900981     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200212000-00003     Document Type: Article

References (49)

1. Kamel OW, Franklin WA, Ringus JC, et al. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 1989;134:107-13.
2. Rudas M, Gnant MF, Mittbock M, et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res Treat 1994;32:165-75.
3. Benini E, Rao S, Daidone MG, et al. Immunoreactivity to MIB-1 in breast cancer: Methodological assessment and comparison with other proliferation indices. Cell Prolif 1997;30:107-15.
4. Barzanti F, Dal Susino M, Volpi A, et al. Comparison between different cell kinetic variables in human breast cancer. Cell Prolif 2000:33:75-89.
5. Molino A, Micciolo R, Turazza M, et al. Estrogen receptors in 699 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1995;34:221-8.
6. 3H]-thymidine labeling index in breast cancer. Cell Prolif 1991;24:437-45.
7. Molino A, Micciolo R, Turazza M, et al. Ki-67 Immunostaining in 322 primary breast cancers: Associations with clinical and pathologic variables and prognosis. Int J Cancer 1997;74:433-7.
8. Siegel S. Nonparametric statistics: for the behavioral sciences. New York: McGraw-Hill, 1956.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
10. Cox DR. Regression models and life tables (with discussion). J R Statis Soc B 1972:34:187-220.
11. SPSS 10.0 for Windows. Chicago: SPSS, 2000.
12. Meyer JS, Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 1979;39:4042-7.
13. Amadori, Silvestrini R. Prognostic and predictive value of thymidine labeling index in breast cancer. Breast Cancer Res Treat 1998;51:267-81.
14. 3H-thymidine labeling index. Int J Cancer 1997;74:122-7.
15. Silvestrini R, Sanfilippo O, Tedesco G. Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer 1974;34:1252-8.
16. Amadori D, Bonaguri C, Nanni O, et al. Cell kinetics and hormonal features in relation to pathologic stage in breast cancer. Breast Cancer Res Treat 1991;18:19-25.
17. Meyer JS, Facher R. Thymidine labeling index of human breast carcinoma: Enhancement of in vitro labeling by 5-fluorouracil and 5-fluoro-2′-dexyuridine. Cancer 1977;39:2524-32.
18. Meyer JS, Prey MU, Babcock DS, et al. Breast carcinoma cell kinetics, morphology, stage, and host characteristics: A thymidine labeling study. Lab Invest 1986;54:41-51.
19. 3H-thymidine labeling index, hormone receptors, and ploidy in breast cancer from elderly patients. Breast Cancer Res Treat 1991;20:19-24.
20. Gasparini G, Dal Fior S, Pozza F, et al. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 1989;14:329-36.
21. Wintzer HO, Zipfel I, Schulte-Monting J, et al. Ki-67 immunostaining in human breast tumors and its relation to prognosis. Cancer 1991;67:421-8.
22. Gottardi O, Tabiadon D, Scanzi F, et al. Clinical and prognostic usefulness of Ki-67 determination in breast carcinoma. Pathologica 1992;84:15-22.
23. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: Pathologic and clinical associations. Br J Cancer 1989;59:943-7.
24. Brown RW, Allred DC, Clark GM, et al. The prognostic significance of cell-cycle kinetics measured by Ki-67 immunocytochemistry in node negative breast cancer. Mod Pathol 1991;4:17.
25. Weikel W, Beck T, Mitze M, et al. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991;18:149-54.
26. Leonardi E, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: Correlation with clinical and biologic variables. J Clin Pathol 1992;45:416-9.
27. Locker AP, Birrel K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: Relation to prognostic variables and short term survival. Eur J Surg Oncol 1992;224-9.
28. Charpin C, Andrac L, Vacheret H, et al. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 1988;48:4368-74.
29. Pierga JY, Leroyer A, Viehl P, et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996;37: 57-64.
30. Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer: Correlation with clinical and pathologic features. Am J Clin Pathol 1991;95:30-4.
31. Gerdes J, Pickartz H, Brotherton J, et al. Growth fraction and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol 1987;129:486-92.
32. Bilous AM, MCkay M, Milliken J. A comparison between Ki-67 antibody reactivity and other pathologic variables in breast carcinoma. Pathology 1991;23:282-5.
33. Barnard NJ, Hall PA, Lemoine NR, et al. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relation to clinical and pathologic variables. J Pathol 1987;152: 287-95.
34. McGurrin JF, Doria MI, Dawson PJ, et al. Assessment of tumor-cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 1987;59:1744-50.
35. Railo M, Nordling S, Boguslawsky K, et al. Prognostic value of Ki-67 immunolabeling in primary operable breast cancer. Br J Cancer 1993;68:579-83.
36. Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation in relation to clinical features and relapse in breast cancer. Cancer 1981;48: 974-9.
37. Tubiana M, Pejovic MH, Koscielny S, et al. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 1989;44:17-22.
38. Hery M, Gioanni J, Lalanne CM, et al. The DNA labeling index: A prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 1987;9:207-12.
39. Meyer JS, Province M. Proliferative index of breast cancer by thymidine labeling index: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 1988;12:191-203.
40. Silvestrini R, Daidone MG, Valagussa P. Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 1989;25:1165-71.
41. O'Reilly SM, Camplejohn RS, Barnes DM, et al. Node-negative breast cancer: Prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 1990;8:2040-5.
42. 3H-thymidinelabeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol 1990;8:1321-6.
43. Paradiso A, Mangia A, Picciarelli M. Fattori prognostici nel carcinoma della mammella operabile N-: Attività proliferativa e caratteristiche clinico-patologiche. Folia Oncol 1992;3:1-13.
44. Clark GM, Mathieu MC, Owens MA, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992;10:428-32.
45. Silvestrini R, Benini E, Daidone MG, et al. P53 as an independent prognostic marker in node-negative breast cancers. J Nat Cancer Inst 1993a;85:965-70.
46. Silvestrini R, Daidone MG, Del Bino G, et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 1993b;4:213-9.
47. Silvestrini R, Daidone MG, Mastore M, et al. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 1993c;11:1150-5.
48. Silvestrini R, Daidone MG, Luisi A, et al. Biologic and clinicopathologic factors as a indicators of specific relapse types in nodenegative breast cancer. J Clin Oncol 1995;13:697-704.
49. Silvestrini R, Luisi A, Zambetti M, et al. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. Int J Cancer 2000;87:405-11.